Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
Open Access
- 1 July 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 55 (9), 2489-2493
- https://doi.org/10.1007/s00125-012-2622-1
Abstract
Aims/hypothesis This study aimed to investigate the associations of plasma levels of the pro-inflammatory cytokine high-mobility group box 1 (HMGB1) with incident cardiovascular disease (CVD) and all-cause mortality in patients with type 1 diabetes. Methods We prospectively followed 165 individuals with diabetic nephropathy and 168 individuals with persistent normoalbuminuria who were free of CVD at study entry and in whom levels of HMGB1 and other cardiovascular risk factors were measured at baseline. Results During the course of follow-up (median, 12.3 years [interquartile range, 7.8–12.5]), 80 patients died, 82 suffered a fatal (n = 46) and/or non-fatal (n = 53) CVD event. After adjustment for age, sex, case–control status and other risk factors, patients with higher levels of loge HMGB1 had a higher incidence of fatal and non-fatal CVD and all-cause mortality: HR 1.55 (95% CI 0.94, 2.48) and HR 1.86 (95% CI 1.18, 2.93), respectively. Further adjustments for differences in markers of low-grade inflammation, endothelial and renal dysfunction and arterial stiffness did not attenuate these associations because plasma levels of HMGB1 were not independently associated with these variables. Conclusions/interpretation In patients with type 1 diabetes, higher levels of plasma HMGB1 are independently associated with a higher risk of all-cause mortality and, to a lesser extent, with a higher incidence of CVD. Larger studies are needed to ascertain more definitely the role of HMGB1 in the development of vascular complications in diabetes.Keywords
This publication has 10 references indexed in Scilit:
- Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications StudyActa Endocrinologica, 2012
- Increased serum high‐mobility group box‐1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non‐diabetic patients with heart failureEuropean Journal of Heart Failure, 2011
- High-Mobility Group Box Protein 1 Neutralization Reduces Development of Diet-Induced Atherosclerosis in Apolipoprotein E–Deficient MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 DiabetesDiabetes Care, 2011
- HMGB1 and RAGE in Inflammation and CancerAnnual Review of Immunology, 2010
- Increased serum HMGB1 is related to the severity of coronary artery stenosisClinica Chimica Acta; International Journal of Clinical Chemistry, 2009
- Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patientsAtherosclerosis, 2009
- HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaquesCardiovascular Pathology, 2007
- Role of HMGB1 in cardiovascular diseasesCurrent Opinion in Pharmacology, 2006
- Increased Expression of the DNA-Binding Cytokine HMGB1 in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2004